| Home | News | Find a Doctor | Ask a Question | Free |
Might Intercytex be seeing alternative technologies, especially “wounding” technologies, like Follica’s, as potentially a superior commercial success compared to Hair Multiplication technology?
And so rather than continuing to spend money developing ICX only to be put out of business by Follica, could Intercytex have decided to wait and see if Follica might succeed?
If you want alternative explanations, here is another one, more possible:
ICX has matured an allogenic version of ICX (cells from a superdonor), and they are going to fasttrack it. In this case, it makes no sense to keep spending resources in TRC. An allogenic version is vastly superior to an autologous one.
Of course, they sell the old technology to Bosley, and make some money HAHA!
| Home | News | Find a Doctor | Ask a Question | Terms of Use & Privacy |
This is an advertising site for paid advertisers to showcase successful hair restoration results only. It is not the mandate of this site to engage in the discussion of failed, unsuccessful procedures, lawsuits, litigations, refunds or complaint cases. Surgical hair restoration procedures carry risks. Please do thorough research, consult your own physician and investigate a doctor's background carefully before making a decision. By proceeding to use our site, you agree to abide by our Terms of Use & Privacy Policy at http://hairsite.com/terms-of-use/ where you can also find a list of HairSite's sponsoring physicians.